Marko Spasic, MD Medical Director, Clinical Science and Safety Clinical Development Biography Marko Spasic, MD, currently serves as Director, Clinical Science and Safety, at PICI. He works across clinical development initiatives to realize the institute’s mission to accelerate the development of breakthrough immune therapies to turn cancer into a curable disease. Dr. Spasic’s focus on delivering novel therapeutic approaches, innovative trial design, as well as the understanding and monitoring of treatment response, to the healthcare community drives him to work at the intersection of medicine, science, and business. Prior to his current position at PICI, Dr. Spasic worked as a Medical Monitor on the PICI microbiome and biomarker studies as well as in business development with IDEAYA Biosciences, a precision oncology company in South San Francisco, helping them through their IPO as well as to identifying key collaborations and partnership opportunities toward bringing new treatments closer to patients. Dr. Spasic is also an Assistant Professor of Clinical Medicine at UCSF. His background and training include residency at UCSF, an MD from UCLA, and a BA in Molecular Biology from UC Berkeley. Through his work with the Yang, Tumeh, and Daud Research Groups, he has received funding through HHMI, AOA, and AANS, and has contributed to over 20 publications including those in Nature and Cell.